Indication intelligence, analysis and sector perception

Juno Therapeutics (JUNO) JCAR015 P2 ROCKET trial on HOLD,

November 23, 2016 8:23am

SELL, pre-market pricing is DOWN -$0.38 or -1.27%

JUNO has voluntarily placed on hold the P2 clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia

The clinical hold was initiated after two patients suffered cerebral edema earlier this week.

One patient died and as of last night the other is not expected to recover.

The Bottom line: Juno has notified the FDA of the voluntary hold and is working with the agency and the Data and Safety Monitoring Board to determine next steps. JUNO is assessing data from the cases and the trial and is evaluating its options regarding the JCAR015 program.

JUNO closed DOWN at $1.56 with 1.07 M shares traded <average volume = 1.495 M>

Further dumping should ensue

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

36 min ago
RegMed Investors (RMi) Closing Bell: I told you so

9 hours 24 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.